A remarkable feature of the carcinogenicity of inorganic arsenic (As i ) is the observation that human exposures to As i have been strongly associated with increases in skin, lung, and internal cancers,but As i does not typically cause tumors in standard laboratory animal test protocols. Considerable controversy has centered on whether there is epidemiological evidence of a ª thresholdº for the carcinogenic effects of As i , or at least of a highly nonlinear dose-response. Saturation of metabolism in the dose-range associated with tumors does not appear to be adequate to produce a major impact on the dose-response for carcinogenicity. If there is a strong nonlinearity, it results from the nature of the carcinogenic mechanism(s) of As i . However, no single hypothesis for the mechanism of As i carcinogenicity has widespread support. A biologically realisticcancer risk assessmentfor As i would require a quantitative description of the dose of active arsenic species in target tissues, the interactions between active arsenic and tissue constituents, and the manner in which these interactions result in tumor formation in multiple organs in humans, but not in experimental animals. Although As i has only infrequently been associated with tumors in animal studies, it has repeatedly been shown to act as a comutagen in vitro and as a cocarcinogen in vivo. As i is clastogenic, producing chromatid aberrations, but does not produce point mutations at single gene loci. Of particular interest, As i has been shown to inhibit repair of DNA single-strand breaks, a possible mechanism for its observed comutagenicity and cocarcinogenicity.We propose a cocarcinogenic mode of action in which As i acts primarily on intermediate cells de® cient in cell cycle control at a late stage in a preexisting carcinogenic process. This interaction enhances genomic fragility and accelerates conversion of premalignant lesions to more aggressive, clinically observable tumors. An indirect effect of As i on DNA repair is consistent with the expectation of a nonlinear dose-response rather than the linear dose-response traditionally assumed for mutagenic carcinogens. However, de® ning the exact nature of this tumor dose-response will require further experimental data on the dose-response for the cellular effects of As i . Because As i carcinogenicity is unlikely to be observed in normal experimental animals not exposed to other carcinogens,studies in animals and cell lines de® cient in cell cycle control should also be considered. Experimental studies speci® cally designed to address the key mechanistic and dose-response issues for As i carcinogenicity are critically needed to support public health policy decisions regarding current environmental exposures to As i .
There is strong evidence from epidemiological studies that exposure to high concentrations of inorganic arsenic (As i ) in air or in drinking water is associated with an increased risk of cancer in human populations. However, there is less certainty regarding the nature of the dose-response relationship, especially in the low-dose region, in the studied populations, and regarding the extrapolation of that dose-response relationship to populations in other parts of the world. In the case of drinking water exposures, As i concentrations clearly associated with tumors in Taiwan (above 0.6 mg/l) are only about an order of magnitude higher than the current maximum contaminant level (MCL) for As i in drinking water in the United States, 0.05 mg/l. Indeed, concentrations of As i in some public water supplies in the Western U.S. can range higher than the MCL (Fan et al. 1994; Kempic 1997) . Such a small apparent margin of safety demands that a solid basis of experimental data and scienti® c understanding underlie any decision regarding the hazards associated with continued use of these water supplies.
The current MCL for As i in drinking water in the United States was originally developed by the United States Public Health Service (USPHS) in the 1940s to protect against the acute toxicityof As i , and was selected to limit the intake of As i in drinking water (at a consumption rate of 2 l/day) to less than 10% of the intake of arsenic in food, which was assumed at the time to be on the order of 1 mg/day (USPHS 1943) . However, more recent analyses estimate daily intakes of arsenic in food to be on the order of 0.05 mg/day, of which only 20±25% is As i (Borum and Abernathy 1994) . Thus ingestion of As i in drinking water at the MCL may actually represent a much greater exposure than that from food ingestion. Moreover, the U.S. Enviromental ProtectionAgency (USEPA) (1988)has estimatedthat consumption of drinking water containing As i at the MCL entails a lifetime risk of skin cancer on the order of 2.5 per thousand, based on dose-response data for skin cancer in a population chronically exposed to high concentrations of As i in drinking water in Taiwan (Tseng 1977; Tseng et al. 1968 ). As a result, the USEPA has for a number of years been attempting to weigh the cost to the public against the potential health bene® ts of reducing the MCL for As i . Much of the controversy surrounding USEPA's reassessment of the MCL has focused on concerns regarding the appropriateness of the USEPA methods for estimating cancer risk at the relatively low As i exposures associated with the consumption of drinking water at the MCL and below (North et al. 1997) .
USEPA estimates of carcinogenic potency, and hence risk, have traditionally been based on the default assumption that risk is linearly related to dose and that any dose, no matter how small, poses some level of risk (USEPA 1987) . However, recent investigations in a number of areas have fueled speculation that the dose-response for As i carcinogenicity is nonlinear and that, mechanistically, a ª thresholdº for As i carcinogenicity may indeed exist (Abernathy et al. 1996) . If this is the case, then characterization of the dose-response relationship for tumors and extrapolation of that relationship to other populations may require a signi® cant departure from traditional risk assessment practices. One alternative would be to develop a biologically realistic dose-response assessment for As i . To be useful, such an assessment should include explicit consideration of the underlying biological processes, and should integrate quanti® cation of the dose of the active arsenic species to the target tissue with the dose-response for those cellular interactions which enhance tumor formation.
Until recently, the available pharmacokinetic and mechanistic information for arsenic has had little impact on quantitative cancer risk assessments for As i , which uniformly followed default guidelinesregardless of chemical-speci® c mechanistic data (USEPA 1987) . However, the regulatory climate has recently changed, particularly with the development of the new USEPA proposed cancer guidelines (USEPA 1996) . The new guidelines, which are already in use within the agency, represent a major departure from the previous USEPA (1987) approach for cancer risk assessment. Important features include: ² De® nition of default approaches as ª no-dataº options, the use of which must be justi® ed based on the lack of suf® cient information to support a more chemical-speci® c approach. ² Explicit support for biologically-basedmodeling as the preferred method for dose-response assessment. ² De® nition of multiple low-dose extrapolation defaults: linear, nonlinear,and margin of exposure (ª thresholdº). ² Consideration of the mode of action (carcinogenic mechanism) of the chemical both for determining the conditions under which the chemical should be considered a cancer hazard for humans, and for determining the appropriate low-dose extrapolation approach.
The new USEPA (1996) guidelines signal an increased level of receptiveness on the part of the agency to consider pharmacokinetic and mechanistic information in developing more chemical-speci® c, scienti® cally based risk assessments. For chemicals such as As i which appear to cause cancer by indirect genomic mechanisms, the use of a nonlinear or margin-ofexposure (MOE) approach can lead to acceptable environmental levels that are very different from those which would result from the traditional linear default. However, departure from the linear default requires experimental information on the shape of the dose-response curve for the carcinogenicity of As i at exposure levels below those associated with observable tumor incidences.
The purpose of the analysis described in this paper was to evaluate the data on As i metabolism, tumorigenicity, and mechanisms of action, and to attempt to integrate these data within a cancer risk assessment context that considers the potential impact of the metabolic and mechanistic data on estimates of acceptable exposure. To accomplish this, the available epidemiological and cancer bioassay data were reviewed to determine the conditions under which As i has been associated with tumors. Information on the metabolism and cellular effects of As i were also evaluated from the viewpoint of their consistency with the observed carcinogenicity of As i ; that is, whether they could provide an explanation for the observed dose-response and the species speci® city of As i -induced tumors. This evaluationserved as the basis for developinga preliminary hypothesis, or integrating framework, for the observed effects of As i . This framework is intended to serve two primary purposes: (1) to promote discussion of the most appropriate strategy for the use of mechanistic information in a cancer risk assessment for As i , and (2) to help identify the nature of the research required to support a mechanism-based cancer risk assessment for As i .
METABOLISM AND DISPOSITION OF INORGANIC ARSENIC
The generally accepted detoxi® cation mechanism of As i in mammals is methylation (Vahter 1994) . Methylation occurs when As i is in the trivalent state (Vahter and Envall 1983; Thompson 1993) , but pentavalent arsenate is readily converted to trivalent arsenite in vivo. Methylationoccurs in the liver, via a saturable enzymatic process, initially forming monomethylarsonic acid (MMAA); a second methyl group can also be added, forming dimethylarsinic acid (DMAA) (Figure 1 ). The methylated arsenic metabolites are less reactive with tissue components than the inorganic forms and are readily excreted in the urine (Vahter 1994) . Although As i is the major initial urinary species following acute exposure, at later times MMAA and DMAA account for more than 95% of the total arsenic excreted in the urine (Mahieu et al. 1981) .
It has been reported that humans have a higher urinary fraction of MMAA than other animal species (Vahter 1994 ). It has
FIGURE 1
Metabolism of arsenic. Pentavalent arsenate is readily converted to trivalent arsenite in vivo. Methylation of arsenite occurs in the liver via a saturable enzymatic process, initially forming monomethyl arsonic acid. MMAA; a second methyl group can also by added, forming dimethylarsinic acid, DMAA.
also been demonstrated that with increasing As i intake in humans, there is a saturation of the second methylation step (from MMAA to DMAA) in short-term exposures (Buchet et al. 1982 (Buchet et al. , 1994 , with evidence for the saturation of DMAA production occurring following ingestion of approximately 200±500 l g As i . Increased organoarsenical ratios (MMAA:DMAA) have been reported in humans chronically exposed to As i concentrations exceeding 0.4 mg/l in drinking water (Cebrian et al. 1994; Warner et al. 1994) , and it has been suggested that changes in the MMAA:DMAA ratio may in some way relate to the observation of carcinogenesis. Increased MMAA:DMAA ratios have also been observed in mice, but only at much higher doses (Hughes et al. 1994) . However, no evidence has yet been presented to suggest that MMAA is responsible for the carcinogenicity of As i . The primary importance of the evidence regarding saturation of metabolism in the human is that exposure to DMAA would change relatively less for drinking water exposures in the tumorigenic range (above 0.6 mg/l). On the other hand, the saturation of the second methylation does not appear to produce any signi® cant nonlinearity in the exposure to the As i species. Linear regression analysis of As i and total arsenic in the urine has been used to determine whether the percentage of As i increases with increasing exposure in humans (Hopenhayn-Rich, Smith, and Goeden 1993) . The results of this analysis failed to show a correlation between percent As i and urinary arsenic concentration; therefore, it was concluded that there was no consistent evidence to support a nonlinear cancer dose-response in humans based on saturation of methylation. Several pharmacokinetic models have been developed for evaluating the kinetic behavior of As i (Mann, Droz, and Vahter 1996a, b; Menzel 1997; Uthus 1997) . Unfortunately, these models focus on the prediction of the urinary elimination of arsenic species under different exposure conditions, rather than estimation of arsenic species concentrationsin the various target tissues associated with As i ' s effects. This de® ciency in the models actually re¯ects the inadequacy of the experimental data available for As i ; there are very little data on the arsenic species concentrations in tissues associated with As i exposures in either experimental animals or humans, and what is available is not in good agreement.
Speciation of the arsenic present at autopsy in tissues from normal Japanese individuals (Yamauchi and Yamamura 1983) demonstrated that nearly all (80 to 100%) of the arsenic in tissues was inorganic, with pentavalent arsenate predominating over trivalent arsenite by a factor of approximately3 to 5. Trivalent arsenite represented roughly 20% of tissue arsenic and ranged from 0.017 to 0.124 ppm wet weight (approximately 0.2 to 1.6 l M). DMAA tissue concentrationsranged from 0.004ppm wet weight (0.05 l M) in the skin to 0.028 ppm wet weight (0.3 l M) in the kidney.
Autopsy analyses of humans exposed to background levels of As i in the vicinity of Glasgow, Scotland, found total arsenic concentrations on the order of 0.03 to 0.15 ppm dry weight in most tissues. Assuming concentrations based on dry weight would be approximately a factor of 4 greater than those based on wet weight (Zhuang et al. 1990 ), these would correspond to concentrations of roughly 0.1 to 0.5 l M. Tissues from different individualsranged from less than 0.01 to more than 1 l M. Concentrations in lung and skin tended to be somewhat higher than in other tissues whereas brain and heart concentrations were lowest (Liebscher and Smith 1968) . Similar studies in Japan found somewhat higher tissue levels, ranging from 0.03 to 0.12 ppm wet weight (about 0.4 to 1.6 l M) in one case (Sumino et al. 1975) , and from 0.04 to 0.8 ppm wet weight (about 0.5 to 10 l M) in another (Yukawa et al. 1980) .
In the case of chronic inhalation exposure to As i in Sweden (Gerhardsson et al. 1988) , the median lung total arsenic concentration in deceased smelter workers was 0.035 ppm wet weight (roughly 0.5 l M), whereas that for controls was 0.005± 0.007 ppm wet weight (roughly 0.1 l M). On the other hand, liver biopsies from four individuals in India exposed chronically to As i in drinking water at concentrations around 0.5 mg/l were on the order of 2 ppm dry weight, or roughly 7 l M .
For comparison with these human concentrationdata, a single oral administration of arsenite to hamsters at a dose representative of those used in chronic animal toxicity studies (4.5 mg As 2 O 3/ kg) achieved peak As i concentrations in kidney and liver of 0.66 and 3.24 ppm wet weight (roughly 10 and 40 l M), respectively (Yamauchi and Yamamura 1985) . Following 6 weeks of daily exposure to a lower dose of arsenic trioxide (0.2 mg As/kg/day, IP), total arsenic concentrationson the order of 5 ppm (67 l M) were observed in both liver and kidney (Flora et al. 1997) . Thus it would appear that tissue total arsenic concentrations routinely achieved in animal studies with As i are signi®cantly greater than those associated with chronic exposures in humans.
REVIEW OF EVIDENCE FOR INORGANIC ARSENIC CARCINOGENICITY
The most striking feature of As i carcinogenicity is the large number of studies unambiguously demonstrating effects in humans. The availability of human data re¯ects the widespread distribution of As i -rich rock formations around the globe, together with the frequent occurrence of human activities that result in exposures. Contamination of well water by natural As i has been reported on several continents, including Asia, North America, and South America. In addition, some ores for important metals, including copper, zinc, and lead, also contain As i , resulting in the release of As i -containing dusts and vapors during processing. Moreover, As i 's properties have made it desirable for uses in medicines and pesticides throughout history. In the late 1960s and 1970s, epidemiological studies associated chronic oral As i exposures with increased risk of developing skin cancer, and chronic inhalation exposures with increased risk of developing lung cancer. More recently, human exposure to As i has also been associated with increased risks of internal cancers. In contrast to these human results, animal studies of As i carcinogenicity have generally failed to demonstrate a tumorigenic response following the administration of As i alone, although there is experimental evidence to support promotional or cocarcinogenic activity for As i or its methylated metabolites. The evidence for the animal and human carcinogenicity and DNA effects associated with As i compounds are described below.
Experimental Animal Studies of Arsenic Carcinogenicity
Oral exposures of experimental animals to As i alone have generally failed to elicit a cancer response. Chronic (2 years or greater) oral As i exposures of rodents that did not produce evidence of increased tumors include exposures of mice and rats to 5 mg/l arsenite in drinking water Schroeder 1967, 1969) , as well as exposures of rats to arsenite or arsenate in food at concentrations 250 or 400 ppm, respectively (roughly 6 mg As/kg/day) (Byron et al. 1967; Kroes et al. 1974 ). On the other hand, intratracheal instillation of 0.07 mg of arsenate did produce bronchogenic adenocarcinoma and bronchiolar/alveolarcell carcinoma in rats (Ivankovic, Eisenbrand, and Preussmann 1979) , although interpretation of the results is complicated by toxicity (10 of the 25 treated rats died of lung necrosis or pneumonia during the ® rst week).
Several studies in experimental animals demonstrate cocarcinogenic activity for As i . In an intratracheal installation study (Ishinishi et al. 1977) , although instillation of arsenic trioxide alone produced only benign lung tumors in rats, when arsenic trioxide was coadministered with the carcinogen benzo-alphapyrene (BaP) it greatly increased the production of lung carcinoma compared to BaP alone, suggesting a cocarcinogenic effect. In another study providing evidence of a synergistic effect of As i on an existing carcinogenic process, arsenite in drinkingwater signi® cantly decreased the time to tumor for spontaneous or transplanted mammary tumors in mice (Schrauzer and Ishmael 1974) . Although As i failed to act as a promoter of skin carcinogenicity in mice (Milner 1969) , the As i metabolite DMAA, when given to rodents following dosing with various initiators, has been shown to increase the incidence of cancers in the lung (Yamanaka et al. 1996) , bladder (Wanibuchi et al. 1997) , kidney, thyroid, and liver .
Epidemiological Studies of Inorganic Arsenic Carcinogenicity
The most widely studied As i -exposed population is located along the southwest coast of Taiwan and includes 42 villages in six townships (Tseng et al. 1968; Tseng 1977) . Because of the high salinity of shallow wells in this area, the studied population used deep artesian wells for drinking water ; alternative water sources did not become generally available until the 1970s . The artesian well water contained As i concentrations ranging from 0.01 to 1.82 mg/l (Tseng 1977) . For comparative purposes, the study population was classi® ed into four groups, according to As i concentrations in the village wells: < 0.1 mg/l (13 villages), 0.1 to 0.29 mg/l (8 villages), 0.3 to 0.59 mg/l (15 villages), and greater than 0.6 mg/l (6 villages) . Overall, 10.6 people per 1000 were found to have skin cancer (Tseng et al. 1968; Tseng 1977) . The male to female ratio was 2.9 to 1, and the prevalence of skin cancer increased with increasing As i concentration in drinking water (Chen et al. 1985; Wu et al. 1989) . As i -induced skin cancer prevalence in the Taiwanese villagers was also correlated with other risk factors including liver dysfunction among carriers of hepatitis B surface antigen, and high consumption of dried sweet potatoes, which may have contained high concentrations of arsenic (Chen et al. 1985 (Chen et al. , 1986 Hsueh et al. 1995) . A sig-ni® cant increase in the incidence of bladder cancer was also reported among residents of the study area, compared to residents elsewhere in Taiwan (Chiang et al. 1988 ). Using age-adjusted mortality rates of this same population, signi® cant associations have been reported between As i levels in well water and mortality from several cancers. Elevated incidences of skin, bladder, kidney, and lung cancers were reported most consistently (Chen et al. 1985 (Chen et al. , 1986 (Chen et al. , 1988b Chen, Kuo, and Wu 1988a; Wu et al. 1989; Chiou et al. 1995) , whereas increases in cancers of the nasal cavity, colon, liver, and prostate have been less frequently identi® ed (Chen et al. 1985 (Chen et al. , 1986 (Chen et al. , 1988b Chen, Kuo, and Wu 1988a; Wu et al. 1989; Chen and Wang 1990) .
The carcinogenicity of As i has also been observed in other regions of the world, including China ), Thailand (Choprapawon and Rodcline 1997) , and India (Chowdhury et al. 1997 ). Most of these reports have been limited to the skin effects of As i . On the other hand, a cohort in Namiki-cho, Japan, comprised of individuals exposed to well water containing As i concentrations greater than 1 mg/l for about 5 years, was reported to have an increased observed standard mortality ratio for both lung and urinary tract cancer relative to expected mortality (Tsuda et al. 1995) . This study also suggested synergism between oral As i intake and smoking for the development of lung cancer. Skin cancers were not directly addressed in this study, although some were present as indicated by comments in the text about skin cancers and Bowen's disease in individuals with lung tumors.
Two towns in the central part of northern Mexico (Region Lagunera) were compared with regard to As i levels in drinking water (Cebrian et al. 1983 (Cebrian et al. , 1994 . The well in El Salvador de Arriba (the exposed population) was found to contain an As i concentration of 0.41 mg/l, whereas the well in San Jose del Vinedo Diego (the control population) had an As i concentration of 0.007 mg/l. Alterations in skin pigmentation,one symptom of As i exposure, were found in 21.6% (64/296) of the individuals exposed to 0.41 mg/l examined compared to 2.2% (7/318) of the ª controlº population (0.007 mg/l). Of the highly exposed individuals found to have pigment alterations, 1.4% had ulcerative zones classi® ed as skin cancer.
In contrast to these positive studies, other studies have been negative or equivocal. A study conducted by B Èorzs Èonyi et al. (1992) in the southeast region of Hungary found no evidence of As i carcinogenicity in residents who were exposed chronically to drinking water that contained As i concentrations exceeding 0.1 mg/l. The study was conducted between 1971 and 1987, with 25,648 people serving as the exposed population and 20,836 people from outlining rural areas exposed to low levels of As i in their drinking water serving as the control population. Levels of arsenic in the hair of the exposed residents were compared to the levels of As i found in the drinking water. It was determined that residents with high hair arsenic levels were exposed to drinking water containing 0.17±0.33 mg/l As i . When the exposed population was compared to the control population, no signi® cant differences in peripheral vascular disorders, peripheral neuropathy, or cancer frequency were observed.
Studies of populations in the United States exposed to drinking water containing As i have also generally been negative or only marginally positive for skin cancer and internal cancers. Among residents of Lane County,Oregon, who consumed drinking water containing As i , no correlation was found between As i levels in drinking water and incidence of skin cancer (Morton et al. 1976) . However, in this study, only 5% of water samples contained 0.1 mg/l or more as compared to 48% of the samples in the studies from Taiwan. Another study used data from Utah respondents to a National Bladder Cancer Study conducted in 1978 to evaluate the association between As i intake, which ranged from 0.0005 to 0.16 mg/l (mean 0.005 mg/l), and bladder cancer (Bates, Smith, and Cantor 1995) . No relationship was found between bladder cancer and either cumulative As i exposure or intake concentration. An ecological study of skin cancer cases in four counties in Montana did not ® nd an increased incidence in the two counties presumed As i -exposed as compared to the control counties (Wong et al. 1992) . No water concentrations are reported in this study. All of the U.S. studies suffer from small cohorts and relatively low As i concentrations, making their interpretation dif® cult.
Although medicinal exposures to arsenicals are not necessarily identical to drinking water exposures, studies of patient populations provide additional data on cancer following oral intake of As i ; in particular, cancers of the skin and internal organs have been reported (Bates, Smith, and Hopenhayn-Rich 1992) . A signi® cant excess in the incidence of bladder cancer mortality and a weak dose-response trend for respiratory cancer have been reported among patients administered more than 0.5 g of potassium arsenite, in the form of Fowler's solution, for periods ranging from 2 weeks to 12 years (Cuzick et al. 1982; Cuzick, Sasieni, and Evans 1992) . It was also noted in these studies that among a subgroup of patients examined for dermatologicalsigns of arsenicism, all cancer deaths occurred among those showing evidence of skin disease (Cuzick et al. 1982; Cuzick, Sasieni, and Evans 1992) .
Inhalation of As i dusts and vapors in occupational settings represents another major route of exposure. Studies of copper smelter worker populations (Tacoma, Washington; Anaconda, Montana; Ronnskar, Sweden; and Magma, Utah) who were exposed to As i via inhalation, reported associations between occupational As i exposure and increased lung cancer mortality rates (Chen and Lin 1994) . Similar studies involving workers at pesticide manufacturing or packaging facilities have also shown excess lung cancer mortality among exposed workers (Ott, Holder, and Gordon 1974; Mabuchi, Lilienfeld, and Snell 1979) .
Analyses of the data regarding respiratory cancer mortality of 2,802 men who worked at a copper smelter in Tacoma, Washington, for one year or more during the period from 1940 to 1964, demonstrated a relationship between the incidence of respiratory, kidney, and bone cancers and As i exposure (Enterline, Henderson, and Marsh 1987; Enterline, Day, and Marsh 1995; Enterline and Marsh 1982) . As i exposures were estimated based on urinary arsenic levels, rather than airborne As i levels (Enterline, Henderson, and Marsh 1987) . A further study of 527 men retired from this copper smelter found that the mortality rate among arsenic trioxide exposed workers was 12.2% higher than that of a comparably unexposed population (Pinto et al. 1977) .
A study of cause-speci® c mortality of workers at a Swedish smelter found a positive dose-response relationship between cumulative As i exposure and lung cancer mortality (Jarup, Pershagen, and Wall 1989; Jarup and Pershagen 1991) . Interestingly, lung cancer mortality was related to estimated average As i exposure, but not to duration.
A relationship between respiratory cancer and As i exposure was also observed among 1,800 men employed at a copper smelter in Anaconda, Montana (Welch et al. 1982) . Exposure levels were categorized as low (< 0.1 mg/m 3 ), medium (0.1± 0.499 mg/m 3 ), high (0.5±4.999 mg/m 3 ), and very high (¸5.0 mg/m 3 ). Potentially confounding factors that were considered included smoking habits and exposures to sulfur dioxide and asbestos. A clear dose-response relationship between As i exposure and respiratory cancer mortality was established, with men exposed to very high As i concentrations having a sevenfold excess above the expected respiratory cancer mortality. Ceiling As i exposure was found to be more important than timeweighted average exposure.
Cancer Risk Estimates
Taken together, the many epidemiological studies conducted on As i -exposed populations clearly demonstrate an increased risk for cancer of the skin, lung, bladder, and perhaps some other internal organs associated with exposure to As i . However, the quantitative relationship between As i exposure and cancer incidence remains a subject of signi® cant debate. The USEPA (1984) used data from the epidemiological studies of the Anaconda (Montana) and ASARCO (Washington) smelters to estimate inhalation risks based upon lung cancer mortality. Based on these studies of smelter workers exposed to As i in dust at concentrations on the order of 1 mg/m 3 , the USEPA (1984) derived a cancer risk of 4.3 per thousand for lifetime inhalation of As i at 0.001 mg/m 3 .
In two separate published analyses, the multistage model of carcinogenesiswas used to analyze inhalationdata, in an attempt to determine whether As i affected the earlier or later stages in the carcinogenicprocess. In both cases, the effects of As i were found most likely to be at late stages of the cancer process (Brown and Chu 1983; Mazumdar et al. 1989 ).
The oral cancer slope factor for As i calculated by the USEPA (1988), 1.5 (mg/kg/day) ¡ 1 , is based upon the incidence of skin cancer reported in the early Taiwanese drinking water studies (Tseng et al. 1968; Tseng 1977) . The associated lifetime risk predicted for ingestion of drinking water containing 0.05 mg/l As i (the current MCL) is 2.5 per thousand. At the time it was developed, it was felt that there was not suf® cient dose-response data to develop a risk estimate based upon the incidence of internal tumors. Upper bound estimates of the overall cancer risk associated with lifetime consumption of drinking water containing 0.05 mg/l As i range as high as 13 per thousand .
Evaluation of the dose-response for cancers in the Taiwanese drinking water exposures is complicated by limitations in the exposure assessments performed in those studies (Brown et al. 1997 ). Nevertheless, a careful re-evaluationof the dose-response for tumors in the Taiwanese population (Brown and Chen 1995) concluded that there was no evidence of excess risk of cancer mortality for exposure to drinking water As i concentrations below 0.1 mg/l. A more recent study of bladder and kidney cancer incidence in the Taiwanese population, in which a more detailed exposure assessment was performed, also found evidence of a highly nonlinear dose-response (Guo et al. 1994) , fueling speculation that a ª thresholdº for the carcinogenicity of As i may exist (Abernathy et al. 1996) .
Genotoxicity Data
Results from in vitro mutagenicity tests of As i with both bacterial or mammalian cells indicate that As i alone is either an inactive or extremely weak mutagen (Rossman et al. 1980; Snow 1992) . Concentrations of As i that are weakly mutagenic are also cytotoxic (Li and Rossman 1989a) . On the other hand, arsenite has frequently been reported to be a comutagen, enhancing the mutagenicity of ultraviolet (UV) radiation and of N -methyl-Nnitro-N -nitrosoguanidine in Escherichia coli (Rossman 1981; Nunoshiba and Nishioka 1987) , of UV and methylmethanesulfonate in Chinese hamster ovary (CHO) cells (Lee, Oshimura, and Barrett 1985) , and of N -methyl-N -nitrosourea in V79 cells (Li and Rossman 1989b) .
In a recent study (Wiencke et al. 1997) , the pZ189 shuttle vector system, a plasmid that can replicate in both mammalian and bacterial cells, was used to determine whether As i alone produced gene mutation and whether As i treatment plus UV irradiation produced a greater mutant frequency than As i treatment or UV irradiation alone. Treatment of human ® broblasts with 5 l M sodium arsenite, but not 1 or 2.5 l M, resulted in a sig-ni® cant increase in pZ189 mutant frequency. Restriction digest and DNA sequencing analyses indicated that arsenite alone produced large-scale rearrangements, frameshifts, and base substitutions. However, when UV-irradiated plasmids were allowed to replicate in human ® broblaststreated with 1, 2.5, or 5 l m sodium arsenite, signi® cant increases in mutation frequency were reported at all As i concentrations, compared to the expected mutation frequency induced by UV radiation alone. The greatest potentiation of UV-induced mutations (4.9-fold) was observed at 1 l M arsenite, a concentrationthat was neither mutagenic nor cytogenic.
Clastogenic effects, such as sister chromatid exchanges (SCEs) and chromosomal aberrations, have also been observed following administration of As i compounds to mammalian cells in vitro (Lee, Oshimura, and Barrett 1985; Barrett et al. 1989; Snow 1992) . In the study reported by Lee, Oshimura, and Barrett (1985) , sodium arsenite (0.8, 3.0, 6.2, or 10 l M) and sodium arsenate (10, 32, 64, or 96 l M) were administeredto Syrian hamster embryo cells in vitro. Chromosomal aberrations and cellular morphological transformations, which increased in a similar dose-dependentmanner, were observed for both As i species. The aberrations consisted primarily of chromatid gaps, breaks, and exchanges, with a few chromosome fragments and dicentrics observed. These aberrations were observed over the same concentration range for which cell transformation was observed, with arsenite being active at lower concentrations than arsenate. SCEs were also observed for both As i species.
These types of clastogenic effects have also been observed in human cells following treatment with arsenite. Signi® cant increases in SCEs and chromatid aberrations compared to controls were observed following treatment with 1 and 2 l M arsenite, respectively (Wiencke and Yager 1992) . When arsenite (0.5±2.0 l M) was administered in combination with the DNA crosslinking agents, diepoxybutane(DEB) or 1,3-butadiene, the incidence of chromasomal aberrations was markedly increased, whereas the induction of SCEs was unaffected (Wiencke and Yager 1992; Yager and Wiencke 1993) . These results indicate that As i acts as a coclastogen, as well as a comutagen. The coclastogenicity of arsenite has also been observed in the case of UV radiation, with maximal effects being noted during the late G1 to early S phase of the cell cycle (Huang et al. 1992) .
A study by Gonsebatt et al. (1997) examined the frequency of lymphocyte chromosomal aberrations and the frequency of micronuclei in exfoliated oral mucosal or urothelial cells in Mexican populations with low or high As i exposure. A sig-ni® cant increase in the frequency of lymphocyte chromosomal aberrations, consisting of chromatid or isochromatid deletions, was reported in the population with high As i exposures (on the order of 0.4 mg/l) when compared to the population with low As i exposures (around 0.02 mg/l). Also, a signi® cant increase in the frequency of micronuclei in oral mucosal epithelial cells or urothelial cells was observed in the population with high As i exposure.
Noncancer Effects of Inorganic Arsenic
Although this analysis is intended to focus on the carcinogenicity of As i , the noncancer effects will be reviewed in order to assess the potential for a common mechanism of action across cancer and noncancer endpoints. To the extent that the interactions between As i and tissues leading to noncancer effects are related to, or are precursors of, the interactions leading to carcinogenicity, it might be possible to utilize information on the dose-response for noncancer effects as a surrogate for the cancer dose-response. Species differences in the dose-response for noncancer effects may also help to understand the reason for the marked species differences in its carcinogenicity. Moreover, appreciation of the dose-response for the noncancer effects of As i is also necessary in order to evaluate the potential impact of a revised As i cancer assessment on water standards such as the MCL. If a nonlinear or MOE approach were to be chosen for the cancer risk assessment for As i , a noncancer effect could well become the driving factor in setting water contamination limits.
In general, trivalent As i compounds produce effects due to the inhibitionof critical sulfhydryl-containingenzymes (Squibb and Fowler 1983) . This inhibitionis typically reversible; the toxicity of trivalent As i can be reduced by the addition of a free thiol such as glutathione,and glutathionedepletion increases toxicity. Binding of As i to dithiols is more dif® cult to reverse. For example, the critical acute effects of As i result from the inhibition of the pyruvate oxidase system, which produces acetyl coenzyme A. The inhibition results from the binding of trivalent As i to the dithiol, lipoic acid, a necessary cofactor for pyruvate oxidase. Because of the avidity of the binding of As i to this dithiol, treatment with another dithiol,British anti-Lewisite, is required to reverse the toxicity.In contrast to the binding-dependentactivity of trivalent As i , pentavalent As i compounds appear to produce toxicity primarily through the similarity of arsenate to phosphate. This similarity results in the formation of unstable arsenate esters in place of phosphate in the important energy source, adenosine triphosphate, leading to an uncoupling of oxidative phosphorylation known as arsenolysis. As discussed in the section on metabolism and disposition, pentavalent As i is readily reduced to trivalent in vivo, complicating interpretation of experimental data. Although tissue speciation data from autopsies suggest that the pentavalent state predominates in vivo, acute As i toxicity generally appears to result from the more potent effects of the trivalent form.
Although the acute toxicity and lethalityof As i occurs at similar doses across species, humans appear to be signi® cantly more sensitive than experimental animals to the chronic noncancer toxicity of As i . Toxicity in chronic animal studies has only been observed for As i doses above 1 mg/kg/day, whereas multiple effects of chronic exposure in humans, particularly vascular effects, have frequently been associated with drinking water exposures of less than 0.1 mg/kg/day (ATSDR 1993) . Moreover, based on an in vitro clonal cytotoxicity assay (Rossman et al. 1997) , normal human diploid® broblasts(ID 50 = 0.6 l M) appear to be much more sensitive to the cytotoxicity of sodium arsenite than Chinese hamster V79 cells (ID 50 = 12.5 l M) or ovary cells (ID 50 = 25 l M). It has been suggested by these investigators that human cells are less resistant to the chronic toxicity of As i due to the lack of an inducible, ef¯ux-mediated tolerance to arsenite (Rossman et al. 1997 ) which has been observed in hamster cells (Wang and Rossman 1993; Wang et al. 1996) . The inducible arsenite tolerance observed in hamster cells involves de novo mRNA and protein synthesis and appears to be distinct from the ª heat shockº response observed for As i and other stressors (Wang, Hou, and Rossman 1994) . Differences in cellular arsenite tolerance could possibly explain the greater susceptibility of humans to the noncancer effects of chronic As i exposure and, perhaps, to the carcinogenic effects as well. However, the relevance of these in vitro observations to chronic exposure in vivo remains to be determined.
Among the Taiwanese population chronically exposed to As i via drinking water, an association between As i exposure levels and increased incidence of peripheral vascular and cardiovascular diseases has been reported (Tseng 1977; Wu et al. 1989 ). Nine people per 1000 were found to have Blackfoot disease, a peripheral vascular disorder resulting in gangrene of the extremities. In persons with Blackfoot disease, the walls of the arteries thicken, harden, and lose elasticity (Tseng et al. 1968 ). The incidence of Blackfoot disease was found to increase with age and As i dose. A clear dose-response was observed using standard mortality ratios from Blackfoot disease in As i -exposed populations compared to populations in areas using shallow wells (Chen et al. 1985) . Increases in hyperpigmentation and keratosis (the formation of horny skin growths) were also observed among this population (Tseng et al. 1968 ).
More recently, alterations in skin pigmentation were found in 21.6% of the individuals examined in a town with an As i drinking water concentration of 0.41 mg/l, as compared to 2.2% of the individuals examined from a town with an As i drinking water concentration of 0.007 mg/l (Cebrian et al. 1994 ). Of the highly exposed individuals found to have pigment alterations, 17.6% had hypopigmentation, 12.2% had hyperpigmentation, 11.2% had palmoplantar keratosis, and 5.1% had papular keratosis (Bowen's disease). Alterations in peripheral vascular circulation were also reported in the highly exposed population. Chen et al. (1995) conducted a study of residents of three villages on the southwestern coast of Taiwan. The residents were evaluated to determine the association between long-term As i exposure in drinking water and hypertension. Factors considered in the study included age, sex, diabetes mellitus, proteinuria, body mass index, and serum triglyceride level. It was determined that with increasing levels of As i in the drinking water, a greater number of cases of hypertension were observed. In another study, a signi® cant dose-response was observed between As i concentration in well water and the prevalence of cerebrovascular disease (Chiou et al. 1997) . In this study the multivariate adjusted odds ratios for cerebral infarction were 1.0, 3.4, 4.5, and 6.9 for consumption of well water with As i concentrations of 0, 0.0001 to 0.05, 0.0501 to 0.2999, and > 0.3 mg/l, respectively.Recent studies have also demonstrated a doseresponse relationshipbetween chronic As i exposureand diabetes mellitus (Lai et al. 1992) , ischemic heart disease , and peripheral vascular disease (Tseng et al. 1996) .
Noncancer effects have also been reported for chronic inhalation of As i . Among workers at a Swedish smelter, mortality from cardiovascular disease was increased twofold in a doserelated manner following occupational As i exposure (Axelson et al. 1978 ). However, Jarup and colleagues(1989) found no relationship between As i exposure and either ischemic heart disease or cerebrovascular disease in this same cohort.
Several of the epidemiological studies have attempted to determine if there is a relationship between other As i -induced diseases and cancers (Chiou et al. 1995; Wu et al. 1989; Tseng et al. 1968 ). Observable lesions have been a particular focus because they might be useful biomarkers. Cancer incidence has been reported to be signi® cantly higher among those with Blackfoot disease after adjustment for As i exposure (Chiou et al. 1995) . As i -induced skin disease also appears to be an indicatorof higher cancer risk (Cuzick, Sasieni, and Evans 1992; Tsuda et al. 1995) . However, there does not appear to be adequate data to determine whether any of the noncancer effects of As i , such as skin keratoses, are precursors to neoplastic lesions, or whether the doseresponse for any of the noncancer effects could be expected to parallel that for cancer.
Noncancer Reference Dose
The USEPA's oral reference dose (RfD) for As i is 0.0003 mg/ kg/day, which equates about 0.01 mg/l, assuming a 70-kg person drinks 2 liters of water per day (USEPA 1998). It was based upon skin changes and possible vascular complications observed in the Taiwanese population exposed to a mean concentration of As i in drinking water of 0.17 mg/l (Tseng et al. 1968; Tseng 1977) ; these effects were not observed in the control population exposed to a mean concentrations of 0.009 mg/l. Important assumptions used in deriving the RfD included estimates that the Taiwanese population drank 4.5 liters of water per day, weighed 55 kg, and ingested 0.002 mg arsenic per day in food. These assumptions were used with the mean drinking water concentrations to derive a no observed adverse effect level (NOAEL) of 0.0008 mg/kg/day and a lowest observed adverse effect level (LOAEL) of 0.014 mg/kg/day. In deriving the RfD, an uncertainty factor of 3 was applied to the NOAEL to re¯ect concerns about human variability and inadequate data on the possibility of reproductive toxicity being a more sensitive endpoint. No inhalation reference concentration (RfC) has been determined for As i .
REVIEW OF POTENTIAL MECHANISMS OF CARCINOGENICITY FOR ARSENIC
Although several mechanisms of action have been proposed for the carcinogenicity of As i , there is at present no hypothesis that enjoys widespread support or that integrates the various clinical observations and the experimental data. Nevertheless, there is general agreement that As i does not appear to act on DNA directly. Instead, the mechanisms of carcinogenicity proposed for As i can be loosely classi® ed as involving promotion or progression (Barrett et al. 1989) ; that is, decreasing the latency for the transformation of preneoplastic lesions into fully expressed malignancy. Several of the proposed mechanisms of action for As i are described below.
Inhibition of DNA Repair/Replication Enzymes
There is strong support in the literature for a mechanism of As i comutagenicity based on the inhibitionof one or more of the proteinsinvolvedin DNA repair and replication (Li and Rossman 1989a, b) . In one study (Li and Rossman 1989b) , sodium arsenite was administered alone or in combination with N -methyl-Nnitrosourea (MNU), a mutagen known to produce DNA single strand breaks (SSBs), to Chinese hamster V79 cells. In the coexposures, cells were initially treated with MNU (1, 2, or 4 mM), followed by sodium arsenite (5 l M for 24 hours or 10 l M for 3 hours). Treatment with As i alone (10 l M, 3 hours) did not result in a signi® cant increase in SSBs. An increase in SSBs was observed 15 minutes following administration of MNU alone; however, 3 hours following MNU administration, the number of SSBs had decreased below controls, indicating that DNA repair had been induced. In contrast, the increased number of SSBs resulting from MNU treatment were not signi® cantly decreased following 3 hours of incubation with arsenite. Based on these results, Li and Rossman (1989b) suggested that arsenite was inhibiting one or more of the enzymes involved in the late stages of DNA repair, e.g., DNA polymerases or ligases.
Further studies were conducted by Li and Rossman (1989a) to determine if arsenite could directly inhibit DNA ligases. Administration of arsenite (10 l M) or MNU (4 mM) alone resulted in the inhibition of total DNA ligase activity to 55% or 25% of control levels, respectively, in the ® rst 40 minutes postadministration. However, 3 hours postadministration with MNU alone, total ligase activity was induced to a level of about 2.5-fold over the control value. Pre-or post-treatment with arsenite inhibited this induction of ligase activity. The inhibition appeared to be primarily directed at DNA ligase II activity. The sensitivities of DNA ligases I and II to arsenite inhibition were also tested in nuclear extracts obtained from V79 cells, either freely dividing or 3 hours after induction with 4 mM MNU. Nuclear extracts prepared in this way primarily contain DNA ligase I (which is primarily involved in replication) or DNA ligase II (which is primarily involved in repair), respectively. Arsenite inhibited the activity of both DNA ligases in these nuclear extracts, with ligase II showing the greater inhibition.However, inhibitiononly occurred at concentrations of several mM, orders of magnitude higher than the concentrations effective in inhibiting repair in the intact cells. This discrepancy suggests that the effects of As i on DNA repair are not due to direct inhibition of the ligases themselves, but rather are due to some indirect effect of As i on the later steps in the repair process. Possible indirect effects include interference of As i with the induction of DNA polymerase or ligase activity in response to DNA damage, inhibition of accessory proteins necessary for DNA repair, or inhibition of other key proteins involved in the cellular control of the DNA repair/replication process.
An interaction with DNA repair/replication processes would also provide an explanation for the gene ampli® cation effects of As i (Barrett et al. 1989; Landolph 1989; Snow 1992; Lee et al. 1985 Lee et al. , 1988 . Gene ampli® cation is a process by which a gene determining the production of a normal cell product becomes multiplied within the genome. Gene ampli® cation can serve as an activation mechanism for ª turning onº oncogenes, by increasing the number of oncogene copies due to a localized replication of DNA (Bohinski 1987; Brodeur et al. 1984) . One source of gene ampli® cation is chromosomal instability and recombination initiated by unrepaired single-strand breaks. Thus it is possible that the inhibition of DNA repair by As i , discussed above, can lead to unrepaired single-strand breaks and subsequent gene ampli®cation. In the study conducted by Lee et al. (1988) , ampli® cation of the dihydrofolate reductase (DHFR) gene was measured in mouse 3T6 cells following administration of sodium arsenite (0.2±6.2 l M) or sodium arsenate (1±32 l M). Dose-dependent increases in ampli® cation of the DHFR gene were observed for both As i species. As with other assays, arsenite was more active, and was active at a lower concentration,than arsenate (Lee, Jan, and Wang 1988) . The concentration ranges associated with ampli® cation were similar to those reported for the repair inhibition (Li and Rossman 1989b) and cell transformation (Lee et al. 1985) effects of As i .
Free Radical Oxidative Damage
Another postulated mechanism for As i carcinogenesis is through the metabolic formation of free radicals and the production of oxidative stress. Several speci® c hypotheses have been proposed including the indirect formation of free radicals as a consequence of the denaturation of proteins by arsenite (Lee and Ho 1994) , or the direct production of a peroxy radical from DMAA (Kato et al. 1994; Yamanaka and Okada 1994) . Yamanaka and Okada (1994) observed signi® cant increases in single DNA strand breaks in the lungs of male ICR mice admin-istered 1500 mg DMAA/kg orally. Increases in strand breakage were transitory reaching a peak 12 hours post-treatment and returning to control levels by 24 hours. No increases in DNA strand breakage were found in the liver, spleen, kidney, testis, or the bone marrow in tested mice. In a second study (Yamanaka et al. 1996) , DMAA was shown to increase the incidence of lung tumors initiated by 4-nitroquinoline-1-oxide. As mentioned earlier, DMAA has also been shown to promote various tumors in rats initiated with a treatment regimen that included diethylnitrosamine, N -methyl-N -nitrosourea, N -butyl-N -(4-hydroxybutyl)nitrosamine, 1,2-dimethylhydrazine, and N -bis-(2-hydroxypropyl)nitrosamine. Increased tumor incidence in bladder, kidney, liver, and thyroid were observed in rats treated with these initiatorsand with DMAA (100 or 400 ppm) for 24 weeks . Similarly, tumor promotion in the bladder by DMAA was examined following initiation with 0.05% N -butyl-N -(4-hydroxybutyl)nitrosamine (Wanibuchi et al. 1997) . In this case, tumor multiplicity was increased with only 10 ppm DMAA. In the DMAA control rats without treatment with the initiator there was toxicity in bladder cells, measured by increased cell proliferation, but no evidence for any initiating activity of DMAA.
In spite of the evidence for the promoting effects of DMAA, a carcinogenic mode of action based on the effects of DMAA would not seem to explain the lack of a carcinogenic response in rodents from treatment with As i at much higher doses than those causing tumors in humans, because rodents can metabolize As i to DMAA with equal or greater capacity than humans. Thus, DMAA-associated oxidative damage of DNA appears unlikely to be the primary determinant of As i carcinogenicity, although a contributing role cannot be ruled out.
Methylation of Tumor Suppressor Genes
It might seem possible that by competing for the methyl donor pool, As i could lead to hypomethylation of DNA. Surprisingly, a study designed to test this hypothesis found just the opposite result in the case of the important tumor suppressor gene, p53. Exposure of human lung adenocarcinoma A549 cells to arsenite (0.08±2.0 l M) or arsenate (30±300 l M), but not DMAA (up to 2000 l M), resulted in hypermethylation of the promoter region of the p53 gene in a small subpopulation of the treated cells (Mass and Wang 1997) . Hypermethylation of a promoter region could silence a tumor suppressor gene such as p53, effectively serving to transform cellsto an altered phenotypeby biochemical effects on the genome distinct from mutation associated with DNA adducts. However, more experimental evidence is required to determine the plausibility and potential signi® cance of this mechanism of As i carcinogenicity.
Overexpression of Growth Factors
Another effect of As i which has been observed at low micromolar concentrations in the case of human keratinocytes is the elaboration of growth factors leading to an increased rate of cell proliferation (Germolec et al. 1996) . Similarly to the case of free-radical initiation from DMAA, it is possible that As i -induced cell proliferation contributes to the incidence of tumors in some tissues. In particular, the hyperproliferative skin keratoses observed in humans exposed chronically to As i may possibly play a preneoplasticrole in the developmentof the basal cell carcinomas and Bowen's disease also induced by As i .
PROPOSED MODE OF ACTION FOR INORGANIC ARSENIC CARCINOGENICITY
The most striking aspect of As i carcinogenicity is its effectiveness in humans and its relative ineffectiveness in multiple animal species. This species difference may arise either due to large quantitative differences in tissue dose of As i in humans compared to rodents or to a qualitative or quantitative difference in the cellular interactions with As i across species. There do not appear to be large differences in tissue exposure to arsenite, at least as indicated by the time-course and the extent of the urinary elimination of arsenic in mice and in human volunteers. However, the actual target tissue concentrations of arsenite and the other arsenic species need to be quantitativelydetermined in humans exposed to tumorigenic drinking water concentrations and compared with tissue concentrations in the various animal studies. In addition, the nature and impact of the inducible tolerance to As i toxicityobserved in hamster cells but not human cells (Rossman et al. 1997 ) must also be further studied, to determine whether it bears any relevance to the carcinogenic effects of As i .
Despite the presence of a number of competing hypotheses regarding the mode of action of As i as a human carcinogen, the overall body of literature reviewed above is most consistent with a central role for arsenite acting as a comutagen (Figure 2) . The activity of arsenite appears to result from an interaction with the proteins responsible for DNA repair and replication. Alteration of these protein functions leads to an increased likelihood of DNA strand breaks and chromosomal alterations. The resulting genomic instability could also be responsible for the gene am-pli® cation noted in cells treated with arsenite, which can in turn serve as an additionalsource of genomic instability.The comutagenicityof As i providesan alternative explanationfor the species speci® city of As i carcinogenicity, because humans are continually exposed to a large array of mutagens in daily life, ranging from cigarette smoke and coffee to a¯atoxin and hepatitis B. By comparison, experimental animals lead a relatively mutagenfree existence unless a coexposure or initiation-promotion experiment is performed. A reasonable, although still hypothetical, mechanism of arsenite carcinogenicity can be formulated based on its in vitro effects on DNA repair and the knowledge that a frequent target site in human cancers is the G1! S interphase cell cycle checkpoint. An important regulatory protein acting at this checkpoint is the p53 tumor suppressor gene product. It appears likely that arsenite and mutations of p53 or other proteins associated with this checkpoint act synergistically to accelerate tumor progression in As i -exposed individuals.
FIGURE 2
Elements in the proposed mode of action for arsenic carcinogenicity. Pharmacokinetic information is used to describe the relationship between exposure to various forms of arsenic in the environment and the concentratiion of the presumed active species, arsenite, in the target tissues. In the proposed mode of action, arsenite binds with vicinal dithiols in critical proteins involved in the ® nal stages of DNA single strand break repair. The inhibition of DNA repair leads to enhanced mutation and genomic instability, particularly in cells with impaired G1! S checkpoint function. Thus arsenite acts primarily as a late-stage carcinogen, principally active on preneoplastic lesions defective in cell replication, resulting in a more rapid appearance of tumors initiated by other carcinogenic insults.
G1! S Interphase Cell Cycle Checkpoint
Mutations in the p53 gene are among the most frequently observed genetic le ions in human cancers. In the most common human cancers, lung, colon, and breast, p53 mutation frequencies range from 50 to 80% (Carbone 1992) . Thus the p53 protein is obviously a critical regulatory protein for maintaining normal cellular function and the p53 pathway a critical site in human carcinogenesis. The product of the p53 gene is a nuclear phosphoprotein which binds DNA and regulates transcription of other genes (Lee, Abrahamson, and Bernstein 1994) . It is involved in cell cycling and becomes phosphorylated in a cell cycle±dependent manner by cdc2 kinase. Several oncogenic viruses, including human papillomavirus and Simian virus 40 (SV40), exert their oncogenic action by directing synthesis of speci® c proteins which bind to and inactivate the p53 protein (Levine 1992) . The p53 protein appears to play a role in G1! S checkpoint arrest in response to DNA damage (Figure 3 ). Other research indicates that p53 is also involved as an effector in initiating programmed cell death, apoptosis (Symonds et al. 1994) , where it affects the same cell death pathway in which the bcl-2 gene product serves as a suppressor (Marin et al. 1994) .
In several types of human cancer, including colorectal cancer, p53 mutations are primarily late events, being only infrequently found in benign adenomas, but more commonly noted in
FIGURE 3
Diagram of the cell division cycle. Checkpoints occur at several points in the cell cycle to provide for the maintenance of DNA integrity. Two are shown in this ® gure: the G1! S checkpoint arrests the cell cycle prior to the initiation of DNA synthesis, in response to unrepaired DNA damage. If damage is too severe, programmed cell death (apoptosis) will be initiated by the p53 gene product. The G2! M checkpoint provides a similar sentinel function prior to mitosis. One of the genes associated with this checkpoint is defective in patients suffering from ataxia-telangiectasia (AT).
aggressive malignant carcinomas (Fearon and Vogelstein 1990, Varmus and Weinberg 1992) . The p53 mutations appear to provide a selective advantage during tumor progression, with other oncogenic changes preceding the p53 mutations that favor cell proliferation. It may be that the p53 mutations serve primarily as a mutator-phenotype, accelerating the conversion of preinitiated cells, which already possess a growth advantage due to protooncogene activation, to more aggressive forms. In accord with this conjecture, the p53 mutation, by itself, enhances malignant progression of nodules, but does not seem to enhance tumor promotion or initiation in skin papilloma initiation-promotion tests (Kemp et al. 1993) . These skin tumor studies were conducted in transgenic mice which lacked functional copies of one or both alleles for the p53 gene. When cells carry signi® cant genetic damage, for instance, from exposure to radiation,they are arrested at the G1! S checkpoint to permit either repair of the DNA damage or apoptosis of the damaged cells. The p53 gene product participates in regulating the arrest of growth at this checkpoint. When cells carry a mutant p53 or when this protein is deleted, cells with DNA damage may proceed through the checkpoint without repair and the chances are increased that further genetic mutations will occur causing progression of initiated cells to more aggressive, malignant phenotypes (Kemp, Wheldon, and Balmain 1994) . In this way, loss or alteration of p53 function then is a critical component in development of many tumors. Because of the importance in surveillance of DNA damage and restricting damaged cells from progressing into S phase, mutations in p53 lead to genetic plasticity, promoting the conversion to more aggressive phenotypes. The role of these mutated p53 proteins in animal tumors, especially the slow growing, noninvasive, localized tumors that predominate in many of the animal bioassay protocols
FIGURE 4
Schematic of the late-stage carcinogenicity of arsenic. Human tumors typically contain a number of genetic mutations (arrows). The effects of arsenic are predominately in altered cells which have lost some functionality associated with the DNA integrity checkpoints (represented here by the p53 gene).
In these cells, arsenic exposure (As) leads to increased genomic fragility, accelerating conversion of slowly growing precursor lesions to more aggressive cancers.
is not at all clear. The rate-limiting step for tumor appearance in these animal tumors may be protooncogene activation instead of tumor-suppressor gene inactivation as noted in the aggressive, highly malignant human tumors. If this is the case, it is no wonder that it has been dif® cult to develop rodent models of As i carcinogenesis.
Arsenite, DNA Repair De cits, and p53 Interactions
Although this discussion has focused on p53, it is not intended to restrict the hypothesis to an interaction of As i with that protein alone. In this discussion, p53 is used as an example of a gene for a regulatory protein which plays an important role in the cell cycle control process and, in particular, in the protection of DNA integrity at the G1! S transition where As i comutagenicityis maximal. What is important for the hypothesis is that the comutagenicity of As i will be more effective in a cell which has lost some element of cell cycle control at the G1! S checkpoint (Figure 4 ). In the case of a functional checkpoint, delayed completion of DNA repair would primarily lead to arrest at the checkpoint, or in extreme cases, apoptosis. However, in cells which have lost some degree of checkpoint function, delayed completion of DNA repair would directly increase the probability of cell division in the face of unrepaired DNA single strand breaks, potentially leading to chromatid aberrations and genomic instability.
Mutational spectra of the p53 gene have been obtained from 13 bladder tumors from As i -exposed individuals in the endemic Blackfoot area of Taiwan (Shibata et al. 1994) . Eight of these tumors had aberrant p53 patterns and the mutations were sequenced. Of the eight, three had double mutations, a rare observation in these transitional cell carcinomas (TCCs) in other human populations. Of the mutants found, one was a two±base pair deletion at codon 229, nine of the 10-point mutations were transitions and only one was a transversion. Of the transitions, three occurred in CpG dinucleotides, two at codon 175, and one at codon 273. The pattern in these tumors differs from other studies of TCC mutations in the United States, Denmark, and Japan where G:C to C:G transversions and a hypermutable AGA to ACA site at codon 280 were frequently involved. The relatively high incidence of double mutations has also been noted in TCCs from heavy smokers (Spruck et al. 1993) . It was suggested that the etiology of the TCCs with these agents may operate through mechanisms that increase the extent of DNA damage per mutational event (Shibata et al. 1994) .
Codon 175 mutations have also been observed in phenacetinassociated urothelial carcinomas, in human colorectal carcinoma, and in squamous cell carcinoma in Egypt and Sweden. Shibata et al. (1994) also suggest that the common occurrence of codon 175 mutation in bladder cancer associated with schistosomiasis, phenacetin, and As i may indicate a common underlying mechanism. A possibility put forward was that these agents caused an increased rate of cell division due to chronic overstimulation of the epithelial cells. Another possibility, however, is that As i may increase the yield of damage per mutational event, not by enhancing proliferation, but by inhibiting repair. Inhibition of natural repair processes associated with As i exposures in these cells with mutated p53 would then accelerate the mutational burden for other important genes leading to rapid progression and development of more aggressive neoplastic disease. Thus the proposed mechanism focuses on a synergistic interaction of As i with preexisting alterations in p53 or other regulatory proteins involved in cell cycle control; it does not propose a direct role of As i in causing the mutations of p53 or of other related proteins.
CONCLUSIONS AND RECOMMENDATIONS
Improving the current cancer risk assessment for As i will require: (1) the development of clearly articulated hypotheses of the mode-of-action of As i as a human carcinogen, (2) speci® c experimentation in appropriate animal species to bolster the evidence for the proposed mechanisms and to rule out competing mechanisms, and (3) a quantitative risk model to integrate pharmacokinetic and mechanistic experimental results and provide expectations of the low-dose risk consistent with the proposed mechanism. This process will develop links between the pharmacokineticsof arsenic in its various forms and the tissue targets with which they interact.
Focusing on a speci® c hypothesis for the mechanism of As i carcinogenesis and creating a database to corroborate, re® ne, or extend the hypothesis are critical for progress in furthering the As i risk assessment. Biologically based dose-response modeling (Moolgavkar 1983; Conolly et al. 1988; Clewell et al. 1995; USEPA 1997 ) based on such a database can then help to capture the essential determinants of the pharmacokineticsof As i and its metabolites as well as of the pharmacodynamics of As i carcinogenesis in order to identify and quantify potential nonlinearities in the process.
A mechanistic hypothesis has been proposed in this report that is consistent with the data showing neoplastic diseases in humans and the failure to produce cancers in experimental animals. This mechanism suggests synergism in human tumors between the comutagenic effects of As i exposure and check-point mutations, such as in the p53 gene, produced by other carcinogenic insults or disease states. Because such a mechanism would be active primarily at the later stages of the carcinogenic process, the synergistic effects of As i exposures may not be appropriately assessed by the application of default cancer risk models. The impact of the mode of action of As i on the expected dose-response for tumorigenicity cannot be estimated until a more complete quantitative database is developed.
The hypothesis stated above is plausible, although still very tentative. It appears to represent the best hypothesis supported by the literature on As i effects. The next step must be to develop the database on tissue exposure, human tumor development, and modes of action necessary to con® rm, refute, or alter this framework for explaining As i carcinogenicity. Important areas in which the database for As i is currently de® cient are discussed below.
Tissue Dosimetry
Collection of additional data in exposed human populations is needed to estimate the target tissue exposures to the various species of arsenic (particularly arsenite and DMAA) associated with increased tumor incidence.Given the large populationscurrently exposed to high concentrations of As i in drinking water, it should be possible to obtain valuable information on arsenic tissue dosimetry. Potential sources of such data include skin and liver biopsies, exfoliated bladder cells, and tissues removed during surgery. It would also be of interest to obtain additional data on tissue concentrations of the various arsenic species (particularly arsenite and DMAA) in experimental animals, both following chronic exposure and in naive animals, in order to look for in vivo evidence of inducible arsenite ef¯ux or other pharmacodynamic responses associated with chronic exposure to As i in experimental animals.
Human Tumor Mutation Data
Cancer is a disease of genes (Varmus and Weinberg 1992) . Altered bases in DNA, the initial macromolecular target, produce protein products with aberrant activity. These alterations may activate protooncogenes to elicit excessive cell growth or inactivate suppressor genes to interrupt the processes that normally act to constrain cell growth. The examination of tumors and the determination of the nature and temporal sequence of mutations in these tumors give some ideas of the required alterations for tumor formation and of the rate-limiting steps in the transformation of normal cells to aggressively malignant tumor cells. This strategy, which has been used to advantage with human colorectal carcinoma (Fearon and Vogelstein 1990) and in a less extensive manner with transitional cell carcinoma of the bladder (Spruck et al. 1994) , should be applied to tumors associated with As i exposure.
In Vitro Studies
Further studies are needed to elucidate the manner in which arsenite interferes with DNA repair/replication. As noted above, studies with DNA ligase II in nuclear extracts do not show a high sensitivity to inhibition by As i . What is the basis of the higher sensitivity of the intact cells? These studies should evaluate the dose-response relationship in normal human and rodent cells as well as in rodent cells that are de® cient in p53 from transgenic animals. Cells transformed with SV40 to block p53 gene product activity could also be examined. Studies must carefully assess the dose-responses for other reported effects of As i as well, such as the cell-proliferative effects of arsenite in epithelial cells.
Transgenic Animal Studies
Another approach for studying the impact of speci® c mutations that has become possible in recent years is the use of transgenic animals which lack certain functionalgenes. When a single gene is inactivated in a mouse strain, these animals are referred to as knockout mice. Thus, a strain of p53 knockout mice has been developed (Donehower et al. 1992; Sands, Donehower, and Bradley 1994) . These animals are normal at birth and develop of a variety of spontaneous neoplasms by 6 months of age (Harvey et al. 1993) . Homozygous p53 de® cient mice (p53¡ / ¡ ) primarily develop lymphomas and hemangiosarcomas; heterozygous mice (p53 + / ¡ ) demonstrate high incidences of osteosarcomas and soft tissue sarcomas. In the p53 (¡ / ¡ ) mice, 50% of the mice had developed tumors by about 20 weeks; in the heterozygous mice, the 50% tumor free mark was not reached until about 80 weeks. Other studies, noted above, have examined the effects of radiation on tumor incidence in these animals and the impact of p53 mutations on initiation,promotion, and progression in the skin (Kemp et al. 1993; Kemp, Wheldon, and Balmain 1994) . Cultured ® broblasts lacking normal p53 or possessing mutated p53 protein have gene ampli® cation frequencies several orders of magnitude higher than cells with wild-type p53 (Yin et al. 1992; Livingstone et al. 1992 ).
Other transgenics have been developed where a mutant p53 has been inserted into the genome. These mice carry the two wild-type alleles and a mutant allele that is under the control of the endogenous p53 promoter (Lavigeur et al. 1989) . Two transgenics were developed; one with an arginine to proline substitution at residue 193 and a second with an alanine to valine change at residue 135. As with the p53 knockout mice, these animals have no gross developmental abnormalities and have an abnormally high incidence of spontaneous tumors. The primary tumor types are lung adenocarcinoma, lymphoma, osteosarcoma, and other sarcoma/adenomas. These transgenic mice, with altered or absent p53 genes, appear to be a promising animal model to examine aspects of As i carcinogenicity and mutagenicity. The choice of transgenic animal to study may at least partially be made based on the spectra of tumor types observed and the extent to which the tumor types resemble As i target tissues in human populations,i.e., lung,liver, kidney, and bladder . Cells from these animals could be obtained to determine dose-response curves for mutagenicity and comutagenicity of As i in normal and p53-de® cient cells. Induction of speci® c tumors by As i in lung, liver, kidney, and bladder might be followed in relatively small groups of these mice. These experiments could be designed both to evaluate incidence of tumor formation and to examine interactionsbetween As i exposures and p53 gene dosage. Once the animal model was established, other tumor incidence studies could look at the interactions between As i in water and tissue-speci® c cytotoxicants or tissue-speci® c mutagens on the incidence of As i -related carcinogenesis. These studies would serve to develop tests for the overall hypothesis of the interaction of As i and cell-checkpoint defects, and to accumulate speci® c parameters for developing a quantitative model of As i carcinogenicity in these animals.
SUMMARY
Epidemiological studies of human populations show an unequivocal association between As i exposure and cancer at multiple tumor sites for As i concentrations above 0.6 mg/l, concentrations which are within an order of magnitude of drinking water concentrations in some regions in the U.S. Responsible public health policy decisions must rely on speci® c evidence related to the shape of the dose-response curve for As i carcinogenicity in the range of concentrations immediately below those associated with the observed effects. Saturation of metabolism does not appear to be adequate to produce a major impact on this dose-response; the shape of the curve in the region of interest will primarily depend on the mode of action of As i as a human carcinogen. Impaired DNA repair leading to enhanced mutability of cells with de® cient cell checkpoint surveillance may underlie the action of As i as a late-stage carcinogen for the observed tumors. This hypothesis needs to be more fully tested by studies to resolve the mechanism by which arsenite interacts with DNA repair and replication, as well as by studies to determine the dose-response relationshipsfor arsenite comutagenesis in normal and checkpoint-de® cient tissues and cell lines. Experimental studies speci® cally designed to address these issues hold the greatest promise to reduce uncertainty in estimating the cancer risks associated with current environmental exposures to As i .
It must be emphasized that, for the purpose of supporting a more accurate risk assessment, qualitative information on the mechanism(s) of carcinogenicity of As i is not, in itself, suf-® cient. To be fully useful in a risk assessment context, mechanistic understanding must drive the identi® cation of speci® c quantitative data which can be used to elucidate the nature of the dose-responsefor the carcinogenicityof As i at current human exposure levels. The ability to demonstrate that the mechanism of carcinogenicity of As i is ultimately nonlinear would have no impact on human risk estimates if the onset of nonlinearity occurred well below current human exposures. Therefore, it is crucial that qualitativemechanistic information be accompanied by quantitative data on the relationship between the concentration of the active arsenic species in the target tissue and the ensuing carcinogenic events in humans. For example, in the case of DNA repair inhibition, the critical data would describe the quantitative relationship between tissue arsenite concentration and the inhibition of DNA repair in appropriate human tissues at concentrationsrelevant to current human exposures. Properly interpreted, perhaps within the framework of a biologically based cancer model, such data should be useful for re® ning estimates of the dose-response for As i -induced tumors.
